Phillip Frost; Chairman of the Board, Chief Executive Officer; OPKO Health Inc Elias Zerhouni; President, Vice Chairman of the Board; OPKO Health Inc Good day. And welcome to the OPKO Health fourth ...

The deal is part of BioReference's ongoing effort to streamline its business to achieve profitability and follows the sale last year of clinical laboratory assets to Labcorp.

Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.

The new acquisitions, Bioverativ and Ablynx, are also part of the growth plan, and Brandicourt and R&D head Elias Zerhouni explained some of the potential benefits of their multi-billion euro outlays.

What we do know, is that Sanofi has begun 2013 on a positive note. Dr Elias Zerhouni, Sanofi’s R&D President, recently announced that there are 65 new molecular entity projects and vaccine ...